CBPE sells Rosemont Pharmaceuticals to Perrigo
CBPE acquired Rosemont in August 2006 for £93m. The sale to Perrigo represents an investment multiple of 3.25x CBPE’s £52m equity investment over the investment period for CBPE’s
Faeth Therapeutics has received the US Food and Drug Administration’s (FDA) fast track designation for the sapanisertib and serabelisib (PIKTOR) with paclitaxel combination to treat advanced or recurrent endometrial cancer.